Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:46:36.638Z.
Calculation as of: 2026-10-06T14:46:36.638Z.
Quote observation: 2026-10-06T14:45:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$122.96M
EV/Sales Ratio
28.73x
TTM Avg
110.46x
3Y Avg
110.46x
5Y Avg
110.46x
Market Cap
$117.86M
EV/Sales Ratio
61.51x
TTM Avg
54.20x
3Y Avg
33.22x
5Y Avg
26.89x
Market Cap
$117.57M
EV/Sales Ratio
4.35x
TTM Avg
33.01x
3Y Avg
61.00x
5Y Avg
61.00x
Market Cap
$116.99M
EV/Sales Ratio
11.70x
TTM Avg
18.19x
3Y Avg
13.45x
5Y Avg
23.44x
Market Cap
$126.43M
EV/Sales Ratio
N/A
TTM Avg
569.53x
3Y Avg
685.92x
5Y Avg
425.88x
Market Cap
$114.65M
EV/Sales Ratio
19.50x
TTM Avg
23.83x
3Y Avg
20.50x
5Y Avg
102.56x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $121.22M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.72M | N/A | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | 28.73x | 110.46x | 110.46x | 110.46x |
| Cibus, Inc. (CBUS)vs › | $123.66M | 31.28x | 52.83x | 97.39x | 88.07x |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.86M | 61.51x | 54.20x | 33.22x | 26.89x |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.57M | 4.35x | 33.01x | 61.00x | 61.00x |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.99M | 11.70x | 18.19x | 13.45x | 23.44x |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | N/A | 569.53x | 685.92x | 425.88x |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.65M | 19.50x | 23.83x | 20.50x | 102.56x |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 3.76x | 3.87x | 7.07x | 9.90x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
